These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 33978871)

  • 21. [Neuropsychiatric disorders in Parkinson's disease].
    Noé-Sebastián E; Irimia-Sieira P; Pomares-Arias E; Martínez-Vila E; Luquin-Piudo MR
    Rev Neurol; 2001 Apr 1-15; 32(7):676-81. PubMed ID: 11391498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine dysregulation syndrome and psychosis in 24-h intestinal levodopa infusion for Parkinson's disease.
    Solla P; Cannas A; Meloni M; Marrosu F
    Parkinsonism Relat Disord; 2016 Oct; 31():144-145. PubMed ID: 27423923
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease.
    Merims D; Shabtai H; Korczyn AD; Peretz C; Weizman N; Giladi N
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1447-53. PubMed ID: 15480845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
    Kulisevsky J; Pagonabarraga J
    Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis.
    Kulick CV; Montgomery KM; Nirenberg MJ
    Parkinsonism Relat Disord; 2018 Sep; 54():40-45. PubMed ID: 29653909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study.
    Sawada H; Oeda T; Umemura A; Tomita S; Hayashi R; Kohsaka M; Yamamoto K; Sudoh S; Sugiyama H
    PLoS One; 2014; 9(1):e85886. PubMed ID: 24497930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can dopamine agonists trigger tactile hallucinations in patients with Parkinson's disease?
    Kataoka H; Sawa N; Sugie K; Ueno S
    J Neurol Sci; 2014 Dec; 347(1-2):361-3. PubMed ID: 25454646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.
    Friedman JH; Agarwal P; Alcalay R; Black KJ; Chou KL; Cote L; Dayalu P; Frank S; Hartlein J; Hauser RA; Lang AE; Marsh L; Marshall F; Moskowitz C; Ravina B; Riley D; Sanchez-Ramos J; Simon DK; Simuni T; Sutton J; Tuite P; Weintraub D; Zesiewicz T
    Int J Neurosci; 2011 Aug; 121(8):472-6. PubMed ID: 21663381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.
    Cabreira V; Soares-da-Silva P; Massano J
    Drugs; 2019 Apr; 79(6):593-608. PubMed ID: 30905034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic exposure to dopamine agonists affects the integrity of striatal D
    Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
    Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?
    Coon EA; Laughlin RS
    J Headache Pain; 2012 Apr; 13(3):255-7. PubMed ID: 22322657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subthalamic nucleus stimulation for Parkinson disease with severe medication-induced hallucinations or delusions.
    Umemura A; Oka Y; Okita K; Matsukawa N; Yamada K
    J Neurosurg; 2011 Jun; 114(6):1701-5. PubMed ID: 21375379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
    Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R;
    Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
    Kitagawa M; Tashiro K
    Intern Med; 2005 Sep; 44(9):939-43. PubMed ID: 16258207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of switching from dopamine agonists to zonisamide on psychiatric and motor symptoms in patients with Parkinson's disease].
    Abe T; Maruyama H
    Rinsho Shinkeigaku; 2021 Jul; 61(7):449-455. PubMed ID: 34148934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.